[Evaluation of the efficacy of xavin treatment of ischemic heart disease].

Abstract

The results of ksavin treatment of 90 patients suffering from ischemic heart disease are discussed. Ksavin was given in a daily dose of 450-1,200 mg for 3 weeks. The clinical efficacy of the treatment was correlated with the risk factors and the indices of the ECG, centra hemodynamics and spiroergometry. The effect was good in 55% of the patients and satisfactory in 30%. No effect was produced in 15% of the patients. The best results were observed in younger patients with disease of short duration and no concomitant arterial hypertension. A favourable effect of ksavin on lipid metabolism and blood coagulation was noted. The study showed ksavin to be an effective measure in the treatment of ischemic heart disease.

• Authors: V P Pomerantsev, N A Ivanova, V S Zadionchenko, A L Vertkin, A I Martynov
• Journal: Kardiologiia (Kardiologiia) Vol. 18 Issue 3 Pg. 36-43 (Mar 1978) ISSN: 0022-9040 [Print] Russia (Federation)
• Vernacular Title: Otsenka éffektivnosti lecheniia bol'nykh ishemicheskoi bolezn'iu serdtsa ksavinom.
• PMID: 347136 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Lipids
• Xanthinol Niacinate
• Theophylline

Topics

• Adult
• Aged
• Blood Coagulation (drug effects)
• Clinical Trials as Topic
• Coronary Disease (drug therapy, physiopathology)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Electrocardiography
• Female
• Hemodynamics (drug effects)
• Humans
• Lipids (blood)
• Male
• Middle Aged
• Prognosis
• Risk
• Theophylline (analogs & derivatives)
• Xanthinol Niacinate (therapeutic use)